Abstract：
BACKGROUND: Lacosamide (LCM) is a third-generation antiseizure medication (ASM) currently approved for the treatment of focal seizures in children aged greater than one month. There are limited data on its efficacy in the neonatal age group. We describe our experience with LCM as an adjunct ASM for the treatment of neonatal seizures.
METHODS: A retrospective chart review over a five-year period (2018 to 2022) was conducted at Le Bonheur Children\'s Hospital to identify neonates with electroencephalography (EEG)-proven seizures who were treated with LCM. Data were collected on electroclinical seizure characteristics, underlying etiology, ASMs, treatment response, and any adverse effects.
RESULTS: A total of 15 neonates with EEG-confirmed seizures who were treated with LCM were included. Ten neonates achieved seizure cessation after LCM was added to their ASM regimen consisting of phenobarbital, levetiracetam, or both. No new treatment-related adverse effects were noted.
CONCLUSIONS: LCM is effective as an adjunct treatment for neonatal seizures. Randomized controlled studies are needed to establish its effectiveness and adequate dosing regimen in this population.
METHODS: A retrospective chart review over a five-year period (2018 to 2022) was conducted at Le Bonheur Children\'s Hospital to identify neonates with electroencephalography (EEG)-proven seizures who were treated with LCM. Data were collected on electroclinical seizure characteristics, underlying etiology, ASMs, treatment response, and any adverse effects.
RESULTS: A total of 15 neonates with EEG-confirmed seizures who were treated with LCM were included. Ten neonates achieved seizure cessation after LCM was added to their ASM regimen consisting of phenobarbital, levetiracetam, or both. No new treatment-related adverse effects were noted.
CONCLUSIONS: LCM is effective as an adjunct treatment for neonatal seizures. Randomized controlled studies are needed to establish its effectiveness and adequate dosing regimen in this population.
摘要：
背景：拉科酰胺（LCM）是一种第三代抗癫痫药物（ASM），目前已被批准用于治疗1个月以上儿童的局灶性癫痫发作。关于其在新生儿年龄组中的疗效的数据有限。我们描述了LCM作为辅助ASM治疗新生儿癫痫的经验。
方法：在LeBonheur儿童医院进行了为期五年（2018年至2022年）的回顾性图表审查，以确定患有脑电图（EEG）证实的癫痫发作的新生儿接受LCM治疗。收集了电临床发作特征的数据，潜在的病因，ASM,治疗反应,以及任何不利影响。
结果：共纳入15例经LCM治疗的经EEG证实的癫痫发作的新生儿。在将LCM添加到苯巴比妥组成的ASM方案中之后，十名新生儿实现了癫痫发作停止。左乙拉西坦,或者两者兼而有之。没有发现新的治疗相关不良反应。
结论：LCM作为新生儿惊厥的辅助治疗有效。需要随机对照研究来确定其在该人群中的有效性和适当的给药方案。
方法：在LeBonheur儿童医院进行了为期五年（2018年至2022年）的回顾性图表审查，以确定患有脑电图（EEG）证实的癫痫发作的新生儿接受LCM治疗。收集了电临床发作特征的数据，潜在的病因，ASM,治疗反应,以及任何不利影响。
结果：共纳入15例经LCM治疗的经EEG证实的癫痫发作的新生儿。在将LCM添加到苯巴比妥组成的ASM方案中之后，十名新生儿实现了癫痫发作停止。左乙拉西坦,或者两者兼而有之。没有发现新的治疗相关不良反应。
结论：LCM作为新生儿惊厥的辅助治疗有效。需要随机对照研究来确定其在该人群中的有效性和适当的给药方案。
